March 22nd 2023
Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.
Addition of Sintilimab to Bevacizumab Biosimilar IBI305 and Chemo Boosts PFS vs Chemo in Advanced EGFR-Mutant NSCLCOctober 6th 2022
Patients with locally advanced or metastatic EGFR-mutant nonsquamous non–small cell lung cancer who progressed on an EGFR inhibitor may benefit from treatment with sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy vs chemotherapy alone.
FDA Approves Bevacizumab-adcd Biosimilar in 6 Cancer TypesOctober 2nd 2022
Based on results from a phase 3 trial, a bevacizumab biosimilar, bevacizumab-adcd, was approved by the FDA for patients with metastatic or recurrent non-squamous non–small cell lung in addition to 5 other disease types.
FDA Approves Oncomine DX Target Test as Companion Diagnostic for RET+ Thyroid Cancer and NSCLCSeptember 28th 2022
The Oncomine Dx Target Test was granted approval by the FDA as a companion diagnostic for RET fusion–positive thyroid cancer and RET fusion–positive non–small cell lung cancer.
Joel W. Neal, MD, PhD Highlights Promise of Cabozantinib ± Atezolizumab in Advanced NSCLC, But Cites Need for More ResearchSeptember 22nd 2022
Findings from the phase 3 COSMIC-021 trial, comparing the effect of cabozantinib alone or in combination with atezolizumab vs docetaxel for advanced non–small cell lung cancer previously treated with immunotherapy, though promising, highlighted further need for randomized data to confirm the regimen’s benefit in the second-line setting, according to Joel W. Neal, MD, PhD.
Selpercatinib Granted Full Approval by the FDA for Locally Advanced/Metastatic RET+ NSCLCSeptember 22nd 2022
Patients with RET fusion–positive locally advanced/metastatic non–small cell lung cancer can now receive treatment with RET inhibitor selpercatinib, which was approved by the FDA.
Catherine A. Shu, MD, on Amivantamab Plus Lazertinib in Previously Treated EGFR+ NSCLCSeptember 20th 2022
At ASCO 2022, Catherine A. Shu, MD, spoke about the CHRYSALIS-2 trial which investigated the use of amivantamab plus lazertinib in patients with EGFR-mutant non–small cell lung cancer following progression on a prior EGFR inhibitor.
ctDNA Reductions Associated With Improved Clinical Outcomes in NSCLC Treated With IOSeptember 16th 2022
Findings from a pooled analysis indicated that a decrease in circulating tumor DNA was associated with improved clinical benefit in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.
Alexander I. Spira, MD, PhD, FACP, Provides an Overview of the Use of Adagrasib in Advanced KRAS G12C–Mutant NSCLC at ASCO 2022September 14th 2022
Alexander I. Spira, MD, PhD, FACP, details the safety profile of single-agent adagrasib in patients with KRAS G12C–mutated advanced or metastatic non–small cell lung cancer, as well as plans for future research following the phase 1/2 KRYSTAL-1 study.
Mary E.R. O’Brien, MBBS, Talks Pembrolizumab in Resected Early-Stage Non–Small Cell Lung Cancer by SubgroupSeptember 13th 2022
Mary E.R. O’Brien, MBBS, discussed results of an exploratory analysis of the phase 3 PEARLS/KEYNOTE-091 study examining pembrolizumab in resected non–small cell lung cancer.
NEOpredict Trial of Nivolumab With or Without Relatlimab Meets Primary End Point of Feasibility in Resectable NSCLCSeptember 9th 2022
Results from the phase 2 NEOpredict trial showed that the primary end point of feasibility of treatment in patients with surgical resection of non–small cell lung cancer was reached in those given preoperative nivolumab plus relatlimab.
Reductions in ctDNA Associated With Improved Clinical Outcomes in NSCLC Treated With an Immune Checkpoint InhibitorSeptember 7th 2022
Findings from a pooled analysis indicated that reductions in ctDNA were associated with improved clinical benefit across multiple end points in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.
Alexander I. Spira, MD, PhD, FACP, Highlights Findings From the Phase 1/2 KRYSTAL-1 Trial of Adagrasib in KRAS G12C–Mutant Advanced NSCLCSeptember 5th 2022
Treatment with adagrasib monotherapy yielded an overall response rate of 42.9% in patients with KRAS G12C–mutated advanced/metastatic non–small cell lung cancer, according to Alexander I. Spira, MD, PhD, FACP.
Edgar Gonzalez-Kozlova, PhD, Emphasizes the Potential for Circulating Soluble Proteins to Predict Response to Immunotherapy in Lung CancerSeptember 2nd 2022
Blood circulating soluble proteins may be an effective and accessible biomarker for predicting response to immunotherapy among patients with squamous cell lung cancer.
Sotorasib Superiority Vs Standard of Care Docetaxel in Previously Treated KRAS G12C–Mutant NSCLCAugust 31st 2022
Patients with previously treated KRAS G12C–mutated non–small cell lung cancer experienced superior survival benefit following treatment with sotorasib compared with docetaxel.
Hossein Borghaei, DO, MS, Discusses the Future of Biomarker Research for Immunotherapy in NSCLCAugust 27th 2022
In an interview with CancerNetwork®, Hossein Borghaei, DO, MS, details the promising body of ongoing research assessing biomarkers in patients with non–small cell lung cancer who are candidates for treatment with immunotherapy.
Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung CancerAugust 24th 2022
Health Canada approved nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer prior to surgery.